Agios Pharmaceuticals (NASDAQ: AGIO) shares climbed 13.8% during the week through Friday morning, fueled by a significant regulatory development for its lead drug candidate.
The Food and Drug Administration announced it would grant priority review for Agios’ oral pyruvate kinase activator, mitapivat, as a treatment for sickle cell disease.
Mitapivat is already approved for treating PK deficiency and thalassemia in adults, making the sickle cell application a major potential expansion of the drug’s commercial reach.
Agios is seeking to position mitapivat as the first oral pyruvate kinase activator approved specifically for sickle cell disease, a distinction that would carry considerable market significance.
PK activators function by improving the health of red blood cells and reducing sickle cell formation, which in turn cuts down on blood vessel blockages, anemia, and painful sickle cell pain crises.
The path to approval is not without complications, as mitapivat produced mixed Phase 3 results, including a failure to meet the primary endpoint of sickle cell pain crisis reduction.
Competitive pressure is also mounting, with Novo Nordisk reporting that its rival oral pyruvate kinase-R activator improved hemoglobin response and demonstrated a statistically meaningful reduction in crisis events.
In June, Agios released more detailed data from its RISE UP trial, noting that patients in the mitapivat-treated group who responded in hemoglobin showed “a clinically meaningful benefit across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes.”
The FDA’s accelerated approval decision is due by November 1, a milestone that investors and analysts are watching closely given the drug’s commercial potential in the sickle cell market.
Any accelerated approval would come with conditions attached, as Agios must demonstrate success in the confirmatory REIGNITE 3 trial to secure full regulatory approval down the line.
The interplay between the mixed trial data and the priority review designation reflects the broader complexity facing Agios as it works to carve out a position in a competitive and rapidly evolving treatment landscape.
For investors, the stock’s sharp weekly gain signals renewed confidence in mitapivat’s prospects, though the road to full approval and commercial success still carries meaningful regulatory and clinical risk.
